Thiogenesis Therapeutics Corp.
Thiogenesis Therapeutics, Corp., a clinical-stage biopharmaceutical company, develops thiol-based therapeutic compounds to treat unmet pediatric medical needs. Its lead product candidate is TTI-0102, a prodrug that consists of cysteamine for use in the treatment of mitochondrial encephalopathy lactic acidosis and stroke-like episodes, leigh syndrome, pediatric metabolic dysfunction-associated ste… Read more
Thiogenesis Therapeutics Corp. (TTI) - Net Assets
Latest net assets as of September 2025: CA$2.15 Million CAD
Based on the latest financial reports, Thiogenesis Therapeutics Corp. (TTI) has net assets worth CA$2.15 Million CAD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CA$3.63 Million) and total liabilities (CA$1.47 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CA$2.15 Million |
| % of Total Assets | 59.4% |
| Annual Growth Rate | 64.95% |
| 5-Year Change | 4009.74% |
| 10-Year Change | N/A |
| Growth Volatility | 62.37 |
Thiogenesis Therapeutics Corp. - Net Assets Trend (2019–2024)
This chart illustrates how Thiogenesis Therapeutics Corp.'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Thiogenesis Therapeutics Corp. (2019–2024)
The table below shows the annual net assets of Thiogenesis Therapeutics Corp. from 2019 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CA$3.43 Million | -38.06% |
| 2023-12-31 | CA$5.53 Million | -7.58% |
| 2022-12-31 | CA$5.98 Million | +9898.29% |
| 2021-12-31 | CA$-61.07K | -173.26% |
| 2020-12-31 | CA$83.35K | -70.26% |
| 2019-12-31 | CA$280.27K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Thiogenesis Therapeutics Corp.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 1395666999.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | CA$17.71 Million | 516.98% |
| Total Equity | CA$3.43 Million | 100.00% |
Thiogenesis Therapeutics Corp. Competitors by Market Cap
The table below lists competitors of Thiogenesis Therapeutics Corp. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
ACCESS Newswire Inc.
NYSE MKT:ACCS
|
$14.25 Million |
|
KWANGJIN WINTEC CO. Ltd
KQ:090150
|
$14.25 Million |
|
Pamel Yenilenebilir Elektrik Uretim AS
IS:PAMEL
|
$14.25 Million |
|
Canfor Pulp Products Inc
PINK:CFPUF
|
$14.25 Million |
|
Nectar Lifesciences Limited
NSE:NECLIFE
|
$14.25 Million |
|
Samhwa Networks Co. Ltd
KQ:046390
|
$14.24 Million |
|
Kocom Co. Ltd
KQ:015710
|
$14.24 Million |
|
Bakrie & Brothers Tbk
JK:BNBR
|
$14.23 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Thiogenesis Therapeutics Corp.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 5,530,134 to 3,425,512, a change of -2,104,622 (-38.1%).
- Net loss of 3,145,730 reduced equity.
- Other factors increased equity by 1,041,108.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CA$-3.15 Million | -91.83% |
| Other Changes | CA$1.04 Million | +30.39% |
| Total Change | CA$- | -38.06% |
Book Value vs Market Value Analysis
This analysis compares Thiogenesis Therapeutics Corp.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 6.38x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 47.30x to 6.38x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | CA$0.01 | CA$0.48 | x |
| 2020-12-31 | CA$0.00 | CA$0.48 | x |
| 2021-12-31 | CA$0.00 | CA$0.48 | x |
| 2022-12-31 | CA$0.15 | CA$0.48 | x |
| 2023-12-31 | CA$0.12 | CA$0.48 | x |
| 2024-12-31 | CA$0.07 | CA$0.48 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Thiogenesis Therapeutics Corp. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -91.83%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.16x
- Recent ROE (-91.83%) is below the historical average (-64.39%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | -26.17% | 0.00% | 0.00x | 1.04x | CA$-101.37K |
| 2020 | -111.19% | 0.00% | 0.00x | 1.76x | CA$-101.01K |
| 2021 | 0.00% | 0.00% | 0.00x | 0.00x | CA$-218.35K |
| 2022 | -65.59% | 0.00% | 0.00x | 1.05x | CA$-4.52 Million |
| 2023 | -91.55% | 0.00% | 0.00x | 1.31x | CA$-5.62 Million |
| 2024 | -91.83% | 0.00% | 0.00x | 1.16x | CA$-3.49 Million |
Industry Comparison
This section compares Thiogenesis Therapeutics Corp.'s net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $2,174,420
- Average return on equity (ROE) among peers: 95.26%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Thiogenesis Therapeutics Corp. (TTI) | CA$2.15 Million | -26.17% | 0.68x | $14.25 Million |
| Innovotech Inc (IOT) | $181.51K | 415.07% | 1.90x | $4.32 Million |
| Rakovina Therapeutics Inc (RKV) | $4.30 Million | -94.74% | 0.45x | $1.14 Million |
| Waverley Pharma Inc (WAVE) | $2.04 Million | -34.55% | 0.71x | $235.88K |